# \_YXOR ETF **Monthly report**

# **IMPORTANT INFORMATION ON RISK FACTORS. PLEASE REFER TO PAGE 2**

# Lyxor UCITS ETF Ibex35 (DR)

# I. Fund Information

## **Investment objective**

The LYXOR UCITS ETF IBEX35 (DR) - D-EUR is a UCITS compliant exchange traded fund that aims to track the benchmark index IBEX 35 Net Return.

IBEX 35 is the domestic and international benchmark for the Spanish Stock Market. IBEX 35, is a tradable index suitable for investment products, designed to represent the performance of the largest securities traded on the Spanish Stock Market. IBEX 35 is made up by the 35 most liquid securities traded on the Spanish Stock Market. Selection criteria of constituents has no sector diversification bias. IBEX 35 constituents are weighted by market capitalisation adjusted by free float.

Lyxor ETFs are efficient investment vehicles listed on exchange that offer transparent, liquid and low-cost exposure to the underlying benchmark index.

## **Trading Information**

Place	Opening Hours (GMT)	Currency	Ticker Bloomberg	RIC Reuters	Distri- bution
Bolsa de Madrid*	08:00 / 16:30	EUR	LYXIB SM	LYXIB.MC	Yes
* First Listing Place of this share class					


First Listing Place of this share class

# **Ticker: LYXIB SM**

#### **Main Fund Characteristics**

Ticker	LYXIB SM
Fund Type	French FCP
Domiciliation	France
UCITS compliant	Yes
ISIN	FR0010251744
UKFRS	Yes
Replication method	Direct (physical)
Sampling	No
Securities Lending	No
Share Class Currency	EUR
Inception Date	19/01/2006
Nav per share at inception (EUR)	121.74
Total Expense Ratio p.a	0.30%
Currency risk	No
NAV per Share (EUR)	86.50
Share AUM (M EUR)	775.64
Total Fund Assets (M EUR)	775.64
Umbrella (M EUR)	-
Minimum Investment (Share)	1
Income treatment	Distribution
Date if distribution	July & December
Last Amount (EUR)	1.25

# II. Index information Source : Bloomberg , Lyxor AM , to Mar 31, 2016



03-11 07-11 11-11 03-12 07-12 11-12 03-13 07-13 11-13 03-14 07-14 11-14 03-15 07-15 11-15 03-16 IBEX 35 Net Return - LYXOR UCITS ETF IBEX35 (DR) - D-EUR - Proforma

### **Index Geographical Allocation**



#### Index Sector Allocation



Financials 31.24% Consumer services 17.37% Utilities 16.34% Industrials 15.92% Telecommunications 11.19% Oil & Gas 4.69% Health care 1.9% Basic materials 1.05% Technology 0.31%

Full name :	IBEX 35 Net Return
Exposure :	Eurozone
Asset Class	Equity
Index type :	Net Total Return
Currency :	EUR
Index Reuters RIC :	.IBEXNR
Index Bloomberg ticker :	IBEXNR
Further information :	www.bolsamadrid.es

### Top ten constituents

Banco Santander Sa	12.76%
Inditex	12.62%
Telefonica Sa	11.19%
Banco Bilbao Vizcaya Argenta	8.49%
Iberdrola Sa	8.48%
Amadeus It Holding Sa-A Shs	3.77%
Repsol Sa	3.26%
Intl Consolidated Airline-Di	3.26%
Ferrovial Sa	3.16%
Abertis Infraestructuras Sa	3.11%

# **III. ETF Performances**

	1 Month	3 Months	6 Months		
Lyxor UCITS ETF Ibex35 (DR)	3.16%	-7.97%	-7.21%	23.17%	2.78%
Lyxor UCITS ETF Ibex35 (DR)-Proforma	3.16%	-7.97%	-7.21%	23.17%	2.75%
IBEX 35 Net Return	3.17%	-8.04%	-7.41%	22.40%	2.25%
Tracking Difference	-0.01%	0.07%	0.19%	0.77%	0.50%
	YTD		2014		
Lyxor UCITS ETF Ibex35 (DR)	-7.97%	-3.85%	7.82%	26.16%	1.06%
Lyxor UCITS ETF Ibex35 (DR) Lyxor UCITS ETF Ibex35 (DR) - Proforma	- <b>7.97%</b> -7.97%	-3.85%	<b>7.82%</b> 7.82%	<b>26.16%</b> 26.16%	<b>1.06%</b> 1.06%
Lyxor UCITS ETF Ibex35 (DR) - Proforma	-7.97%	-3.85%	7.82%	26.16%	1.06%

Performances related to distributing ETF are calculated reinvesting dividends into the Performances related to distributing L I hare calculated reinvesting dividends into the ETF performance. Pro Forma NAV: NAV: Adv. calculated when using the current benchmark as the unique benchmark: since inception Performance gap represents the performance differences between the ETF Pro forma and the Index The Tracking from represents the annualised volatility of the performance differences between the ETF and the benchmark.

Changes of benchmark may occur. To compare the track of the ETF with its benchmark, we will use the below indexes:

	From	То
MSCI SPAIN	19/01/2006	10/04/2006
IBEX 35	10/04/2006	01/06/2011
IBEX 35 Net Return	01/06/2011	

Source: Bloomberg, Lyxor AM, to Mar 31, 2016

The figures relating to [past performances / simulated past performances / past performances and simulated past performances] refer or relate to past periods and are not a reliable indicator of future results. This also applies to historical market data.

CLIENT SERVICES | +33 (0)1 42 13 31 31 | www.lyxor.com | client-services@lyxor.com



### **Risk Factors**

It is important for potential investors to evaluate the risks described below and in the fund prospectus which can be found on www.lyxoretf.com CAPITAL AT RISK: ETFs are tracking instruments: Their risk profile is similar to a direct investment in the Underlying Index. Investors' capital is fully at risk and investors may not get back the amount originally invested.

REPLICATION RISK: The fund objectives might not be reached due to unexpected events on the underlying markets which will impact the index calculation and the efficient fund replication

UNDERLYING RISK: The Underlying Index of a Lyxor ETF may be complex and volatile. When investing in commodities, the Underlying Index is calculated with reference to commodity futures contracts exposing the investor to a liquidity risk linked to costs such as cost of carry and transportation. ETFs exposed to Emerging Markets carry a greater risk of potential loss than investment in Developed Markets as they are exposed to a wide range of unpredictable Emerging Market risks. CURRENCY RISK: ETFs may be exposed to currency risk if the ETF is denominated in a currency different to that of the Underlying Index they are tracking. This means that exchange rate

fluctuations could have a negative or positive effect on returns.

Includion and a negative of positive energy of restrict and the second and the se market-maker systems; or an abnormal trading situation or event

#### Investor's Notice

#### This factsheet is for professional clients only.

This document is of a commercial nature and not of a regulatory nature

It is each investor's responsibility to ascertain that it is authorised to subscribe, or invest into this product.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice

LYXOR UCITS ETF IBEX35 (DR) is a Fonds commun de placement (French mutual fund), approved by the Autorité des marchés financiers (AMF) in accordance with provisions of the Directive 2009/65/EC (the "2009 Directive").

Société Générale et Lyxor International Asset Management (« Lyxor AM »), recommend that investors read carefully the "risk factors" section of the product's prospectus and the "Risk and reward" section of the Key Investor Information Document (KIID). The prospectus in French and the KIID in French are available free of charge on www.lyxoretf.com or upon request to client-services@lyxor.com.

Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them.

Updated composition of the product's investment portfolio is available on www.lvxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product. and might also be mentioned on the websites of the stock exchanges where the product is listed.

There is no guarantee that the fund's objective will be met. The fund may not always be able to replicate exactly the performance of the index (or indices). This product includes a risk of capital loss. The redemption value of this product may be less than the amount initially invested. In a worst case scenario, investors could sustain the loss of their entire investment.

The index referred to herein (the "Index") is not sponsored, approved or sold by Société Générale, Lyxor AM. Société Générale, Lyxor AM shall not assume any responsibility in this respect The accuracy, completeness or relevance of the information which has been drawn from external sources is not guaranteed although it is drawn from sources reasonably believed to be reliable. Subject to any applicable law, Société Générale, Lyxor AM shall not assume any liability in this respect.

The market information displayed in this document is based on data at a given moment and may change from time to time.

This document does not constitute an offer for sale of securities in the United States of America. The product herein described will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States of America without being registered or being exempted from registration under the U.S. Securities Act.

This factsheet is issued by Lyxor Asset Management (Lyxor AM), société anonyme à directoire et conseil de surveillance having its registered office at 17 cours Valmy, 92800 Puteaux (France), 418 862 215 RCS Nanterre, authorized and regulated by the Autorité des marchés financiers (AMF). Lyxor AM is represented in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by Financial Conduct Authority in the UK.

This document is issued by the London Branch of Societe Generale. Societe Generale is a French credit institution (bank) authorised and supervised by the Autorite de Contrôle Prudentiel (the French Prudential Control Authority)" and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority. Details about the extent of our authorisation and regulation by the Prudential Regulation Authority, and regulation by the Financial Conduct Authority are available from us on request.

